C

Concord Biotech Ltd
BSE:543960

Watchlist Manager
Concord Biotech Ltd
BSE:543960
Watchlist
Price: 1 107.1 INR -5.75% Market Closed
Market Cap: ₹115.8B

Relative Value

The Relative Value of one CONCORDBIO stock under the Base Case scenario is 1 318.83 INR. Compared to the current market price of 1 107.1 INR, Concord Biotech Ltd is Undervalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CONCORDBIO Relative Value
Base Case
1 318.83 INR
Undervaluation 16%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Multiples Across Competitors

CONCORDBIO Competitors Multiples
Concord Biotech Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Concord Biotech Ltd
BSE:543960
121.8B INR 10.8 37.6 26.9 31.5
US
Eli Lilly and Co
NYSE:LLY
987.6B USD 16 51.8 34.8 37.3
US
Johnson & Johnson
NYSE:JNJ
565.6B USD 6 21 14.6 17.9
CH
Roche Holding AG
SIX:ROG
280.6B CHF 4.6 30 12.7 14.8
UK
AstraZeneca PLC
LSE:AZN
214.9B GBP 5.1 31.7 15.1 22.1
CH
Novartis AG
SIX:NOVN
223.4B CHF 5.2 20.2 12.7 16.4
US
Merck & Co Inc
NYSE:MRK
291.6B USD 4.5 15.2 10.7 12.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.9 11 12.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
146.4B USD 2.3 14.8 7.5 10.3
FR
Sanofi SA
PAR:SAN
97.3B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
IN
C
Concord Biotech Ltd
BSE:543960
Average P/E: 24.7
37.6
15%
2.5
US
Eli Lilly and Co
NYSE:LLY
51.8
54%
1
US
Johnson & Johnson
NYSE:JNJ
21
6%
3.5
CH
Roche Holding AG
SIX:ROG
30
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
38%
0.8
CH
Novartis AG
SIX:NOVN
20.2
17%
1.2
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
2%
8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
C
Concord Biotech Ltd
BSE:543960
Average EV/EBITDA: 44.3
26.9
18%
1.5
US
Eli Lilly and Co
NYSE:LLY
34.8
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.6
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
CH
Novartis AG
SIX:NOVN
12.7
6%
2.1
US
Merck & Co Inc
NYSE:MRK
10.7
6%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
C
Concord Biotech Ltd
BSE:543960
Average EV/EBIT: 92.6
31.5
17%
1.9
US
Eli Lilly and Co
NYSE:LLY
37.3
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.9
6%
3
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
22.1
23%
1
CH
Novartis AG
SIX:NOVN
16.4
12%
1.4
US
Merck & Co Inc
NYSE:MRK
12.8
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3